BridgeBio is a a clinical-stage bioteccompany focused on discovering and developing drugs for patients with grievous genetic diseases. BridgeBio has built a portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology. The drugs are in various phases of development, from pre-clinical to late-stage.